3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
NET
1
Endocrine
1
CNS
1
Conditions
Paraganglioma
6
Meningioma
6
Pheochromocytoma
5
Neuroendocrine Tumors
4
Neuroblastoma
3
Medulloblastoma
2
Glioma
2
Glioblastoma
2
Ependymoma
2
Sarcoma, Synovial
1
Recurrence
1
Pituitary Neoplasms
1
Parathyroid Neoplasms
1
Osteosarcoma
1
Neoplasms, Germ Cell and Embryonal
1
Hypertension
1
Gastro-enteropancreatic neuroendocrine tumor
1
Esthesioneuroblastoma, Olfactory
1
Diffuse Intrinsic Pontine Glioma
1
Central Nervous System Neoplasms
1
Carcinoma, Medullary
1
Adrenal Gland Neoplasms
1
Adrenal Cortex Neoplasms
1
Interventions
Docetaxel
8
Radiotherapy
6
Filgrastim
5
Cisplatin
5
Radiotherapy, Intensity-Modulated
3
Etoposide
3
Erlotinib Hydrochloride
3
Chemotherapy, Adjuvant
3
Cetuximab
3
Capecitabine
3
Bevacizumab
3
sargramostim
2
Peripheral Blood Stem Cell Transplantation
2
Paclitaxel
2
Gemcitabine
2
Cyclophosphamide
2
Carboplatin
2
Acupuncture Therapy
2
vandetanib
1
tumor necrosis factor-alpha, CNGRC fusion protein, human
1
tanespimycin
1
pentetreotide
1
oncogene protein E7, Human papillomavirus type 16
1
olaparib
1
oblimersen
1
lutetium Lu 177 dotatate
1
etoposide phosphate
1
entinostat
1
enasidenib
1
cevimeline
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esthesioneuroblastoma, Olfactory
×
lutetium Lu 177 dotatate
×
CNS
×
Clear all
NCT06607692
2026-06-04
LUPARPED
Fundación de investigación HM
Phase 1/2
Recruiting
25 enrolled